Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
J Neurointerv Surg. 2024 Jan 12;16(2):151-155. doi: 10.1136/jnis-2023-020128.
Although national organizations recognize the importance of regionalized acute ischemic stroke (AIS) care, data informing expansion are sparse. We assessed real-world regional variation in emergent AIS treatment, including growth in revascularization therapies and stroke center certification. We hypothesized that we would observe overall growth in revascularization therapy utilization, but observed differences would vary greatly regionally.
A retrospective cross-sectional analysis was carried out of de-identified national inpatient Medicare Fee-for-Service datasets from 2016 to 2019. We identified AIS admissions and treatment with thrombolysis and endovascular thrombectomy (ET) with International Classification of Diseases, 10th Revision, Clinical Modification codes. We grouped hospitals in Dartmouth Atlas of Healthcare Hospital Referral Regions (HRR) and calculated hospital, demographic, and acute stroke treatment characteristics for each HRR. We calculated the percent of hospitals with stroke certification and AIS cases treated with thrombolysis or ET per HRR.
There were 957 958 AIS admissions. Relative mean (SD) growth in percent of AIS admissions receiving revascularization therapy per HRR from 2016 to 2019 was 13.4 (31.7)% (IQR -6.1-31.7%) for thrombolysis and 28.0 (72.0)% (IQR 0-56.0%) for ET. The proportion of HRRs with decreased or no difference in ET utilization was 38.9% and the proportion of HRRs with decreased or no difference in thrombolysis utilization was 32.7%. Mean (SD) stroke center certification proportion across HRRs was 45.3 (31.5)% and this varied widely (IQR 18.3-73.4%).
Overall growth in AIS treatment has been modest and, within HRRs, growth in AIS treatment and the proportion of centers with stroke certification varies dramatically.
尽管国家组织认识到区域性急性缺血性脑卒中(AIS)治疗的重要性,但提供扩展数据的信息却很少。我们评估了紧急 AIS 治疗中的真实区域差异,包括血管再通治疗的增长和卒中中心认证。我们假设会观察到血管再通治疗利用率的总体增长,但观察到的差异在区域上会有很大的不同。
对 2016 年至 2019 年期间国家医疗保险按服务收费数据集进行了回顾性的横截面分析。我们使用国际疾病分类,第 10 次修订版,临床修正代码识别 AIS 入院和溶栓及血管内血栓切除术(ET)治疗。我们根据达特茅斯医疗保健医院转诊区域(HRR)的医疗保健医院地图集将医院分组,并计算每个 HRR 的医院、人口统计学和急性脑卒中治疗特征。我们计算了每个 HRR 的卒中认证医院比例和接受溶栓或 ET 治疗的 AIS 病例比例。
共有 957958 例 AIS 入院。2016 年至 2019 年,每个 HRR 接受血管再通治疗的 AIS 入院比例的相对平均(SD)增长率为溶栓治疗 13.4(31.7)%(IQR -6.1-31.7%),血管内血栓切除术治疗 28.0(72.0)%(IQR 0-56.0%)。血管内血栓切除术利用率无差异或减少的 HRR 比例为 38.9%,溶栓利用率无差异或减少的 HRR 比例为 32.7%。HRR 间的平均(SD)卒中中心认证比例为 45.3(31.5)%,差异很大(IQR 18.3-73.4%)。
AIS 治疗的总体增长幅度较小,而在 HRR 内,AIS 治疗的增长和具有卒中认证的中心比例差异很大。